Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00075400 · OUTCOME

Duration of Progression Free Survival

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer · Source last updated 2019-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Inter-Quartile Range
Time frame
CT scan or MRI if used to follow lesion for measurable disease every other cycle for the first 6 months; up to 5 years

What was measured

Progression is defined according to RECIST v1.0 as at least a 20% increase in the sum of LD target lesions taking as reference the smallest sum LD recorded since study entry, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or unequivocal progression of existing non-target lesions.

Analysis population: Eligible and treated patients.

Groups in this outcome

Gleevec

Gleevec™ 600 mg QD po continuously (a cycle will be defined as 28 days). If first cycle of Gleevec™ at 600 mg QD is tolerated without any significant toxicity, the dose can be escalated to 400 mg BID po Q 12 hours until disease progression or adverse effects prohibit further therapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Gleevec23

Reported measurements

Source class 1
Values in months · Interval/dispersion: Inter-Quartile Range
GroupValueSpreadLowerUpperComment
Gleevec1.6099Not reported0.91992.1027Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.9199
        upper Limit
        2.1027
        value
        1.6099
denoms
  1. counts
    1. group Id
      OG000
      value
      23
    units
    Participants
description
Progression is defined according to RECIST v1.0 as at least a 20% increase in the sum of LD target lesions taking as reference the smallest sum LD recorded since study entry, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or unequivocal progression of existing non-target lesions.
dispersion Type
Inter-Quartile Range
groups
  1. description
    Gleevec™ 600 mg QD po continuously (a cycle will be defined as 28 days). If first cycle of Gleevec™ at 600 mg QD is tolerated without any significant toxicity, the dose can be escalated to 400 mg BID po Q 12 hours until disease progression or adverse effects prohibit further therapy.
    id
    OG000
    title
    Gleevec
param Type
MEDIAN
population Description
Eligible and treated patients.
reporting Status
POSTED
time Frame
CT scan or MRI if used to follow lesion for measurable disease every other cycle for the first 6 months; up to 5 years
title
Duration of Progression Free Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice